A González-Celestino, Y González-Osorio, C García-Iglesias, A Echavarría-Iñiguez, A Sierra-Mencía, A Recio-García, J Trigo-López, A Planchuelo-Gómez, M L Hurtado, L Sierra-Martínez, M Ruiz, M Rojas-Hernández, C Pérez-Almendro, M Paniagua, G Núñez, M Mora, C Montilla, C Martínez-Badillo, A G Lozano, A Gil, M Cubero, A Cornejo, I Calcerrada, M Blanco, A Alberdí-Iglesias, C Fernández-de-Las-Peñas, A L Guerrero-Peral, D García-Azorín
{"title":"Differences and similarities between COVID-19 related-headache and COVID-19 vaccine related-headache. A case-control study.","authors":"A González-Celestino, Y González-Osorio, C García-Iglesias, A Echavarría-Iñiguez, A Sierra-Mencía, A Recio-García, J Trigo-López, A Planchuelo-Gómez, M L Hurtado, L Sierra-Martínez, M Ruiz, M Rojas-Hernández, C Pérez-Almendro, M Paniagua, G Núñez, M Mora, C Montilla, C Martínez-Badillo, A G Lozano, A Gil, M Cubero, A Cornejo, I Calcerrada, M Blanco, A Alberdí-Iglesias, C Fernández-de-Las-Peñas, A L Guerrero-Peral, D García-Azorín","doi":"10.33588/rn.7710.2023063","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Headache is a frequent symptom at the acute phase of coronavirus disease 2019 (COVID-19) and also one of the most frequent adverse effects following vaccination. In both cases, headache pathophysiology seems linked to the host immune response and could have similarities. We aimed to compare the clinical phenotype and the frequency and associated onset symptoms in patients with COVID-19 related-headache and COVID-19 vaccine related-headache.</p><p><strong>Subjects and methods: </strong>A case-control study was conducted. Patients with confirmed COVID-19 infection and COVID-19-vaccine recipients who experienced new-onset headache were included. A standardised questionnaire was administered, including demographic variables, prior history of headaches, associated symptoms and headache-related variables. Both groups were matched for age, sex, and prior history of headache. A multivariate regression analysis was performed.</p><p><strong>Results: </strong>A total of 238 patients fulfilled eligibility criteria (143 patients with COVID-19 related-headache and 95 subjects experiencing COVID-19 vaccine related-headache). Patients with COVID-19 related-headache exhibited a higher frequency of arthralgia, diarrhoea, dyspnoea, chest pain, expectoration, anosmia, myalgia, odynophagia, rhinorrhoea, cough, and dysgeusia. Further, patients with COVID-19 related-headache had a more prolonged daily duration of headache and described the headache as the worst headache ever experienced. Patients with COVID-19 vaccine-related headache, experienced more frequently pain in the parietal region, phonophobia, and worsening of the headache by head movements or eye movements.</p><p><strong>Conclusion: </strong>Headache caused by SARS-CoV-2 infection and COVID-19 vaccination related-headache have more similarities than differences, supporting a shared pathophysiology, and the activation of the innate immune response. The main differences were related to associated symptoms.</p>","PeriodicalId":21281,"journal":{"name":"Revista de neurologia","volume":"77 10","pages":"229-239"},"PeriodicalIF":0.8000,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10831767/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de neurologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33588/rn.7710.2023063","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Headache is a frequent symptom at the acute phase of coronavirus disease 2019 (COVID-19) and also one of the most frequent adverse effects following vaccination. In both cases, headache pathophysiology seems linked to the host immune response and could have similarities. We aimed to compare the clinical phenotype and the frequency and associated onset symptoms in patients with COVID-19 related-headache and COVID-19 vaccine related-headache.
Subjects and methods: A case-control study was conducted. Patients with confirmed COVID-19 infection and COVID-19-vaccine recipients who experienced new-onset headache were included. A standardised questionnaire was administered, including demographic variables, prior history of headaches, associated symptoms and headache-related variables. Both groups were matched for age, sex, and prior history of headache. A multivariate regression analysis was performed.
Results: A total of 238 patients fulfilled eligibility criteria (143 patients with COVID-19 related-headache and 95 subjects experiencing COVID-19 vaccine related-headache). Patients with COVID-19 related-headache exhibited a higher frequency of arthralgia, diarrhoea, dyspnoea, chest pain, expectoration, anosmia, myalgia, odynophagia, rhinorrhoea, cough, and dysgeusia. Further, patients with COVID-19 related-headache had a more prolonged daily duration of headache and described the headache as the worst headache ever experienced. Patients with COVID-19 vaccine-related headache, experienced more frequently pain in the parietal region, phonophobia, and worsening of the headache by head movements or eye movements.
Conclusion: Headache caused by SARS-CoV-2 infection and COVID-19 vaccination related-headache have more similarities than differences, supporting a shared pathophysiology, and the activation of the innate immune response. The main differences were related to associated symptoms.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
